Ascletis Pharma has dosed the first obese or overweight subjects in the 13-week, multi-centre US Phase IIa trial of ASC30.

As obesity management draws awareness and weight-loss injections are launched in India, hospitals are offering customised ...

Endoscopic gastric remodeling reduced GERD symptoms and dependence on proton pump inhibitors in patients with obesity, according to a new study.

A clinical guidance from the American College of Cardiology Solution Set Oversight Committee states that pharmacotherapy may ...

Obesity, a growing global epidemic, is identified as a significant, modifiable risk factor for ovarian cancer, a deadly ...

Sarcopenic obesity, a hidden condition affecting people over 40, causes muscle loss and fat gain without major weight changes ...

Insurance companies should not drag their feet. They must take meaningful steps to ensure that obesity treatment is easily ...

This study sends a hopeful message: Cancer survivors can take charge of their health. A healthy lifestyle—avoiding obesity, ...

A higher proportion of sleep medicine providers vs. patients reported CPAP over tirzepatide as their preferred treatment option for comorbid obesity and obstructive sleep apnea, according to data ...

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.

Novo Nordisk has launched Wegovy in India, an anti-obesity drug aimed at managing weight and reducing cardiovascular risks.

Researchers found that once-monthly maridebart cafraglutide led to substantial weight loss and improved glycemic control in ...